A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
Because it is glucose-dependent, this class carries a low intrinsic hypoglycaemia risk on its own — the risk arrives when it is combined with insulin or a sulfonylurea, which usually need reducing.
What I am trying to establish is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.
I would rather have one careful answer than five confident ones.
SallyK_inj said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
My labs after 3 months on glycaemic control: A1C 5.8%, fasting glucose 83 mg/dL, fasting insulin 6 uIU/mL. My endo says these are "textbook perfect."
For context, my baseline A1C was 8.1% and fasting glucose was 118 mg/dL. The improvement has been dramatic and consistent.
LarryQC_SD said:My labs after 3 months on glycaemic control: A1C 5.8%, fasting glucose 83 mg/dL, fasting insulin 6 uIU/mL.
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:
| Biomarker | Association | Evidence Level |
|---|---|---|
| Baseline BMI | Higher BMI → greater absolute weight loss | Strong |
| Fasting insulin | Higher insulin → better response | Moderate |
| GLP1R gene variants | rs6923761 → variable response | Preliminary |
| Baseline hsCRP | Higher CRP → greater CV benefit | Moderate |
| Early weight loss (4 wk) | ≥3% at 4 wks → strong predictor of ≥10% at 68 wks | Strong |
The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsSallyK_inj said:A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.
Second this.
Adding the clinical framing, because it changes how the question reads.
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:
| Test | Baseline | Month 3 | Month 6 | Month 12 |
|---|---|---|---|---|
| Glucose (fasting) | 116 | 106 | 92 | 84 |
| Insulin (fasting) | 22 | 14 | 8 | 7 |
| HOMA-IR | 4.5 | 4.2 | 2.0 | 1.5 |
| Uric Acid | 8.9 | 6.6 | 5.9 | 5.2 |
The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.